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Inflammasomes have emerged as playing key roles in inflammation
and innate immunity. A growing body of evidence has suggested
that the nucleotide-bindingdomain and leucine-rich repeat protein–3
(NLRP3) inflammasomeis important in chronicairwaydiseases suchas
asthma and chronic obstructive pulmonary disease. Inflammasome
activation results, in part, in pro–IL-1b processing and the secretion
of theproinflammatory cytokine IL-1b. Becauseasthmaexacerbations
are associated with elevated concentrations of secreted IL-1b, we
addressed whether the NLRP3 inflammasome is activated under
in vitro conditions that mimic infectious exacerbations in asthma. Pri-
mary cultures of airway smoothmuscle (ASM) cells were treated with
infectious stimuli (mimicked using the Toll-like receptor–2 agonist
Pam3CSK4, a synthetic bacterial lipopeptide).Whereas Pam3CSK4 ro-
bustlyup-regulatedASMcytokineexpression inresponsetoTNF-aand
significantly enhanced IL-1b mRNA expression, we were unable to
detect IL-1b in the cell supernatants. Thus, IL-1b was not secreted
and therefore was unable to act in an autocrine manner to promote
the amplification of ASM inflammatory responses.Moreover, Toll-like
receptor–2 ligation did not enhanceNLRP3 or caspase-1 expression in
ASM cells, and NLRP3 and caspase-1 protein were not present in the
ASM layer of tracheal sections from human donors. In conclusion,
these data demonstrate that the enhanced synthetic function of
ASM cells, induced by infectious exacerbations of airway inflamma-
tion, is NLRP3 inflammasome–independent and IL-1b–independent.
Activation of the NLRP3 inflammasome by invading pathogens may
prove cell type–specific in exacerbations of airway inflammation in
asthma.
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Inflammasomes control innate immunity and inflammation. By
regulating the processing and release of proinflammatory cytokines
(predominantly IL-1b), burgeoning evidence supports a key role
for inflammasome activation in lung diseases such as asthma and
chronic obstructive pulmonary disease, as recently reviewed (1,
2). The nucleotide-binding domain and leucine-rich repeat pro-
tein–3 (NLRP3) inflammasome has been best characterized, and
both in vivo and in vitro models of allergic asthma and asthmatic
inflammation have demonstrated an important role for the NLRP3
inflammasome in the amplification and potentiation of inflamma-
tion during airway disease (3–5). Because elevated IL-1b protein
secretion was suggested to play a role in asthma exacerbation (5,
6), we were interested in exploring whether the NLRP3 inflamma-
some is activated under in vitro conditions that mimic infectious
exacerbations in asthma.
The NLRP3 inflammasome is a multimeric intracellular pro-
tein complex consisting of three domains: NLRP3, the apoptosis-
associated speck-like protein containing the caspase activation
and recruitment domain, and caspase-1 (7). The sensor protein
NLRP3 regulates inflammasome assembly in a temporal and
spatial manner (8). NLRP3 expression is inducible, and mRNA
regulation can take place at the transcriptional and posttranscrip-
tional levels (9, 10). Recognition of invading pathogens by the
NLRP3 domain results in the assembly of three components to
form a stable inflammasome, which in turn activates pro–caspase-1
into active caspase-1 autocatalytically (1). Caspase-1 is a cysteine
protease that cleaves inactive precursors of IL-1b into bioactive
cytokine, which is then competent to be secreted out of the cell.
During the past decade, the ability of airway smooth muscle
(ASM) cells to produce and secrete proinflammatory mediators,
including cytokines and chemokines, has been established by
many studies, as reviewed elsewhere (11, 12). Furthermore, ac-
cumulating evidence has shown that the treatment of ASM cells
with IL-1b in vitro augments the production of numerous proin-
flammatory mediators, including IL-6, IL-8 (13), IL-17A (14),
prostaglandin E2 (15), and matrix metalloproteinase–9 (16),
thus serving to amplify airway inflammation. The enhanced syn-
thetic function of ASM may play a pivotal role, leading to acute
exacerbations of asthma, by provoking and amplifying airway
inflammatory responses (17, 18). To date, however, most NLRP3
inflammasome studies have been limited to airway epithelium
and macrophages (19). The possible involvement of the NLRP3
inflammasome and IL-1b activation in the enhanced synthetic
function of ASM cells in response to invading pathogens remains
largely unexplored.
Intriguingly, our previous studies revealed an important cell-
type difference in human airways. Whereas NLRP3 and caspase-1
were present in human lung epithelium, as shown by Hirota and
colleagues (19) and confirmed here, these proteins were not
present in dissected ASM strips, and neither were they detected
by immunohistochemistry in human tracheal sections. These in
situ data support our in vitro studies, where the engagement of
Toll-like receptor 2 (TLR2) with the TLR2 agonist Pam3CSK4
exerted no effect on NLRP3 and caspase-1 expression. These
(Received in original form January 29, 2013 and in final form April 10, 2013)
*These authors contributed equally to this work.
J.A.H. is a recipient of Canadian Institutes of Health Research, Integrated and
Mentored Pulmonary and Cardiovascular Training strategic training, the Michael
Smith Foundation for Health Research, and AllerGen NCE postdoctoral training
fellowships. Doctoral students were supported by an Endeavour Postgraduate
Award (M.M.R.), an International Postgraduate Research Scholarship (N.N.R.),
and the Senglet Stiftung (Switzerland) (M.M.). A.J.A. was funded by project
grants from the National Health and Medical Research Council of Australia.
Correspondence and requests for reprints should be addressed to Alaina J.
Ammit, Ph.D., Respiratory Research Group, Faculty of Pharmacy, Building A15,
Room S222, University of Sydney, New South Wales 2006, Australia. E-mail:
alaina.ammit@sydney.edu.au
This article has an online supplement, which is accessible from this issue’s table of
contents at www.atsjournals.org
Am J Respir Cell Mol Biol Vol 49, Iss. 4, pp 517–524, Oct 2013
Copyright ª 2013 by the American Thoracic Society
Originally Published in Press as DOI: 10.1165/rcmb.2013-0047OC on May 13, 2013
Internet address: www.atsjournals.org
results suggest that because of the absence of these key com-
ponents, NLRP3 inflammasome activation will not be possible,
and consequently IL-1b will not be processed for secretion. Our
data support this assertion, because we show that although
TLR2 ligation increased TNF-a–induced IL-1b mRNA expres-
sion, IL-1b is not secreted from ASM cells. Thus, the NLRP3
inflammasome is not activated in ASM upon TLR2 ligation.
MATERIALS AND METHODS
Human ASM Cell Culture
Human bronchi were obtained from patients undergoing surgical resec-
tion for carcinoma or from lung transplant donors, in accordance with
procedures approved by the Sydney South West Area Health Service
and the Human Research Ethics Committee at the University of Syd-
ney. A minimum of three different ASM primary cell cultures estab-
lished from individual patients was used for each experiment, in
accordance with established procedures (20). Unless otherwise speci-
fied, all chemicals used in this study were purchased from Sigma-
Aldrich (St. Louis, MO).
Real-Time RT-PCR
Total RNAwas extracted using the RNeasyMini Kit (Qiagen, Doncaster,
Victoria, Australia), and reverse-transcribed using the RevertAid First
Strand cDNA Synthesis Kit (Fermentas Life Sciences, Hanover, MD).
Real-time RT-PCR was performed on an ABI Prism 7500 (Applied Bio-
systems, Foster City, CA) with IL-1b (TaqMan ID:Hs01555410_m1), IL-6
(Hs00174131_m1), IL-8 (Hs00174103_m1), NLRP3 (Hs00918082_m1), and
18S ribosomal RNAmeasured with TaqMan probes (Applied Biosystems)
TABLE 1. SUBJECT CHARACTERISTICS
Immunohistochemistry Samples Age (yr) Sex Status Weight (kg) Height (cm) Cause of Death
Donor 1 19 F Not asthmatic 87 165 Head trauma, MVA
Donor 2 20 F Not asthmatic 72.2 165 Head trauma
Donor 3 25 M Asthmatic 103 185 Anoxia
Immunoblot Samples
Donor 4 11 M Not asthmatic 49.9 157 CVA
Donor 5 26 F Asthmatic 91.6 168 Anoxia, probable asthma attack
Donor 6 20 M Asthmatic 81.2 172.7 Head trauma
Definition of abbreviations: CVA, cardiovascular attack; MVA, motor vehicle accident.
Figure 1. Time course of TNF-a–induced IL-1b mRNA ex-
pression and augmentation by Pam3CSK4 (in comparison
with IL-6 and IL-8 mRNA temporal kinetics). Growth-
arrested airway smooth muscle (ASM) cells were pre-
treated with vehicle or Pam3CSK4 (1 mg/ml) for 1 hour,
followed by treatment with vehicle or TNF-a (10 ng/ml)
for 0, 1, 2, 4, 8, and 24 hours. (A) IL-1b, (B) IL-6, and (C)
IL-8 mRNA expression was quantified by real-time RT-PCR,
and the results are expressed as fold increase compared
with vehicle-treated cells at 0 hour (mean 6 SEM values
from n ¼ 7 primary ASM cell cultures). Statistical analysis
was performed using two-way ANOVA, and then the Bon-
ferroni post hoc test (where an asterisk denotes a significant
effect of treatment on mRNA expression, compared with
vehicle-treated cells; xsignificant effect of Pam3CSK4 on
TNF-a–induced mRNA expression at the same time point;
P , 0.05). h, hours.
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or caspase-1 (PPH00105B) and 18S (PPH0566E) measured by SYBR
Green RT2 qPCR Primer Assays (Qiagen).
ELISAs
IL-1b (DuoSet DY201; R&D Systems, Minneapolis, MN), IL-6 (BD
OptEIA 555220; BD Biosciences, San Diego, CA), and IL-8 (BD
OptEIA 555244; BD Biosciences) ELISAs were performed according
to the manufacturers’ instructions.
IL-1b Neutralization
To neutralize IL-1b, conditioned media from treated ASM cells or IL-1b
recombinant protein (R&D Systems) were incubated for 1 hour at 378C
with 2 mg/ml of either vehicle, normal mouse IgG1 (Santa Cruz Biotech-
nology, Santa Cruz, CA) as an isotype control, or a monoclonal mouse
IgG1 antibody to human recombinant IL-1b (clone 8516; R&D Systems).
Immunoblotting of ASM Cell Lysates
NLRP3 or caspase-1 in ASM cells was detected by immunoblotting with
rabbit anti-human NLRP3 (HPA012878; Sigma-Aldrich) or caspase-1
polyclonal antibodies (catalogue number 2225; Cell Signaling Technology,
Danvers, MA), compared with a-tubulin as the loading control (mouse
monoclonal IgG1, DM1A; Santa Cruz Biotechnology). Primary antibod-
ies were detected with goat anti-mouse or anti-rabbit horseradish perox-
idase–conjugated secondary antibodies (Cell Signaling Technology), and
visualized by enhanced chemiluminescence (PerkinElmer, Wellesley,
MA). Lysates from THP-1 monocyte cells treated with and without
phorbol myristate acetate (50 ng/ml) served as positive controls (19).
Human Lung Tissue
Human tracheas were obtained from lungs donated for medical research
at the International Institute for the Advancement ofMedicine (Edison,
NJ) (19). Tracheas from three individual patients were used for each
experiment. For the immunohistochemical analysis of NLRP3 and
caspase-1 in human tracheas, tissue was fixed in 10% formalin and
processed for immunohistochemistry (see the online supplement). For
the immunoblotting of NLRP3 and caspase-1, tracheas were stored in
Krebs solution, and then ASM was isolated and protein was extracted
for immunoblotting (see the online supplement). For subject character-
istics, please see Table 1.
Statistical Analysis
Statistical analysis was performed using either the Student unpaired
t test or two-way ANOVA, followed by the Bonferroni post hoc test.
P , 0.05 was considered sufficient to reject the null hypothesis for all
analyses. Data represent means 6 SEMs.
RESULTS
Time Course of TNF-a–Induced IL-1b mRNA Expression
and Augmentation by Pam3CSK4
We measured the temporal kinetics of TNF-a–induced IL-1b
mRNA expression in ASM cells, and examined whether the
TLR2 agonist, Pam3CSK4, up-regulated IL-1b concentrations.
As shown in Figure 1A, TNF-a significantly enhanced IL-1b
mRNA expression over time, with significant expression observed
Figure 2. Pam3CSK4 potentiates TNF-a–induced IL-6 and
IL-8 protein secretion, but IL-1b is not secreted from ASM
cells. Growth-arrested ASM cells were pretreated with ve-
hicle or Pam3CSK4 (1 mg/ml) for 1 hour, followed by
treatment with vehicle or TNF-a (10 ng/ml) for 0, 1, 2,
4, 8, and 24 hours. ELISAs were used to measure (A) IL-1b,
(B) IL-8, and (C) IL-6 protein secretion. Note that IL-1b
secretion from ASM cells (A) was not detected. Statistical
analysis was performed using two-way ANOVA and then
the Bonferroni post hoc test (where an asterisk denotes
a significant effect of treatment on protein secretion, com-
pared with vehicle-treated cells; xsignificant effect of
Pam3CSK4 on TNF-a–induced protein secretion at the
same time point; P , 0.05). Data represent the mean 6
SEM values from n ¼ 4 primary ASM cell cultures.
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as early as 1 hour, and a peak of 90.4- 6 18.4-fold at 2 hours,
before subsiding to concentrations that were not significantly dif-
ferent from those of vehicle controls by 8 hours (P , 0.05).
Pam3CSK4 alone also significantly enhanced IL-1b mRNA ex-
pression, with a significant 14.8- 6 8.4-fold increase observed
at 4 hours (P , 0.05). Importantly, TNF-a–induced IL-1b up-
regulation was significantly potentiated by Pam3CSK4 (P ,
0.05). As shown in Figure 1A, the effect of Pam3CSK4 on
TNF-a–induced IL-1b mRNA was first observed at 2 hours
(although not significantly), and this effect increased to sig-
nificant levels at 4 hours, and by 24 hours was measured at
337.0- 6 48.0-fold, compared with 23.0- 6 14.9-fold using
TNF-a alone (P , 0.05).
Interestingly, when we compared the temporal kinetics of IL-1b
mRNA expression with those of IL-6 (Figure 1B) and IL-8
(Figure 1C), we also observed a later significant up-regulation
of TNF-a–induced cytokine secretion at 24 hours (P , 0.05).
This raises the intriguing possibility that the early phase of IL-1b
mRNA may undergo translation, to result in IL-1b protein se-
cretion that can then act back on ASM cells in an autocrine
manner to stimulate the cytokine mRNA expression observed
at 24 hours. Thus, we hypothesize that the TLR2 agonist,
Pam3CSK4, activates the inflammasome to result in IL-1b se-
cretion from ASM cells and the potentiation of cytokine se-
cretion from ASM cells.
Pam3CSK4 Potentiates TNF-a–Induced IL-6 and IL-8
Protein Secretion, but IL-1b Is Not Secreted from ASM cells
To address this hypothesis, we measured concentrations of IL-
1b, IL-6, and IL-8, as secreted from ASM cells over 0 to 24
hours. As shown in Figures 2B and 2C, respectively, Pam3CSK4
pretreatment significantly enhanced TNF-a–induced IL-6 and
IL-8 at 24 hours (Figures 2A and 2B; P , 0.05), in confirmation
of our earlier report (18). We then attempted to measure IL-1b
in the same supernatants, using an ELISA that had been con-
firmed able to measure secreted IL-1b that resulted from
inflammasome activation (21). Importantly, IL-1b was not
detected (Figure 2A), suggesting that even though IL-1b mRNA
was up-regulated, the inflammasome was not activated and IL-1b
was not secreted from ASM cells.
Neutralization of IL-1b in Conditioned Media Exerts No Effect
on Cytokine Secretion
To confirm that IL-1b was not secreted from ASM cells, we used
an IL-1b–neutralizing antibody. We initially validated IL-1b
neutralization by incubating a range of concentrations of IL-
1b recombinant protein (1–500 pg/ml) with IL-1b–neutralizing
antibody, and measured its inhibitory effect on IL-1b–induced
IL-6 and IL-8 protein secretion. As shown in Figure 3, IL-1b
induced a concentration-dependent augmentation of IL-6 and
IL-8 protein secretion in vehicle-treated or isotype control–treated
ASM cells, with no significant difference between cells treated
with vehicle or the isotype control. Importantly, the neutrali-
zation of IL-1b reduced IL-6 protein secretion from ASM cells
in response to a range of IL-1b concentrations (1–500 pg/ml;
Figure 3A), with only 79.5 6 39.8 pg/ml IL-6 secreted in
response to 500 ng/ml IL-1b preincubated with the IL-1b–
neutralizing antibody, as opposed to approximately 150-fold greater
amounts of IL-6 secretion after preincubation with the isotype
control (P , 0.05). Similarly, this down-regulation by IL-1b neu-
tralization was also observed in IL-8 protein secretion, as depicted
in Figure 3B.
We next examined whether the neutralization of IL-1b in
conditioned media exerted any effect on IL-6 and IL-8 protein
secretion by ASM cells. As shown in Figure 4A, the removal of
IL-1b by the neutralizing antibody exerted no effect on the
amount of IL-6 secreted in response to conditioned media from
cells stimulated with TNF-a alone or Pam3CSK4 1 TNF-a.
Similarly, IL-8 secretion in response to conditioned media pre-
incubated with IL-1b–neutralizing antibody was not significantly
different from that preincubated with the isotype control (Figure
4B). As a positive control, we confirmed IL-1b neutralization
Figure 3. Effect of IL-1b–neutralizing antibody on IL-6 and
IL-8 protein secretion induced by IL-1b recombinant pro-
tein. To validate the effect of neutralization antibody on
IL-6 (A) and IL-8 (B) protein secretion, vehicle or increasing
concentrations of IL-1b recombinant protein (1–500 pg/
ml) were incubated for 1 hour at 378C with 2 mg/ml of
vehicle, isotype control, or IL-1b–neutralizing antibody,
and then added to growth-arrested ASM cells for 24 hours.
IL-6 and IL-8 protein secretion was measured by ELISA.
Statistical analysis was performed using two-way ANOVA
and then the Bonferroni post hoc test (where an asterisk
denotes a significant effect of IL-1b–neutralizing antibody
on protein secretion, compared with the isotype control;
P , 0.05). Data represent the mean 6 SEM values from
n ¼ 3 primary ASM cell cultures.
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with ASM cells treated with 100 ng/ml IL-1b recombinant pro-
tein in parallel experiments. As shown in Figures 4C and 4D, IL-
1b neutralization significantly inhibited IL-6 and IL-8 secretion
from ASM cells, compared with the isotype control (P , 0.05).
Pam3CSK4 Does Not Affect TNF-a–Induced NLRP3 mRNA
and Protein Expression in ASM Cells
NLRP3 is an important component of the inflammasome, and
has been shown to be up-regulated under inflammatory condi-
tions. Caspase-1 also plays an important role in inflammasome
function, to cleave precursor pro–IL-1b into mature IL-1b. Col-
lectively, our data thus far demonstrate that the Pam3CSK4-
mediated augmentation of TNF-a–induced IL-6 and IL-8 mRNA
and protein concentrations is not mediated by IL-1b secre-
tion. Thus, these results indicate that components of the
NLRP3 inflammasome may not be up-regulated in ASM cells
upon TLR2 activation. To address this, we measured NLRP3
and caspase-1 mRNA expression in response to Pam3CSK4
and TNF-a, alone and in combination, over time (0–24 h). As
shown in Figure 5A, neither Pam3CSK4 nor TNF-a exerted a
significant effect on NLRP3 mRNA expression over 24 hours.
Moreover, the temporal kinetics of NLRP3 mRNA expres-
sion was not affected in response to Pam3CSK4 1 TNF-a in
combination. Importantly, we were unable to detect NLRP3 pro-
tein in the lysates of human ASM cells, in confirmation of our
mRNA results. As shown in Figure 5C, NLRP3 protein was not
detected, or up-regulated, by treatment with Pam3CSK4 or TNF-
a, alone or in combination. We also measured the temporal kinet-
ics of caspase-1 mRNA expression in response to Pam3CSK4 1
TNF-a, alone and in combination (Figure 5B). Whereas TNF-a
induced a small (z 3-fold) but significant effect on caspase-1
mRNA expression at 8 hours (P , 0.05), this did not result in
changes in caspase-1 protein (Figure 5D). Importantly, Pam3CSK4
did not up-regulate TNF-a–induced caspase-1 mRNA and protein
expression. Taken together, these results suggest that because
NLRP3 and caspase-1 protein are not present in ASM cells,
the NLRP3 inflammasome is not activated upon TLR2 ligation.
Thus, IL-1b is not secreted from ASM cells.
NLRP3 and Caspase-1 Are Not Expressed in ASM from Human
Tracheal Tissue
We then investigated whether NLRP3 and caspase-1 are pres-
ent in human tracheas in situ, using immunohistochemistry
and immunoblot analyses of protein isolated from ASM
strips freshly dissected from human tracheas. As shown via
immunohistochemistry, whereas the epithelial layer is positive
Figure 4. The neutralization of IL-1b in conditioned media
exerts no effect on cytokine secretion. Conditioned media
were prepared by removing supernatants from ASM cells
treated with TNF-a or Pam3CSK4 1 TNF-a for 1, 2, 4, 8,
and 24 hours. Conditioned media were incubated at 378C
for 1 hour with 2 mg/ml of either IL-1b–neutralizing anti-
body or isotype control, and then incubated with ASM
cells for 24 hours. The resultant (A) IL-6 and (B) IL-8 protein
in the supernatants was measured by ELISA. Results were
expressed as a percentage of TNF-a–induced cytokine in
isotype control at 1 hour. To confirm IL-1b neutralization,
parallel experiments were conducted with vehicle or IL-1b
recombinant protein (100 pg/ml) treated under identical
conditions, and (C) IL-6 and (D) IL-8 were measured by
ELISA. Statistical analysis was performed using the Student
unpaired t test (where an asterisk denotes a significant ef-
fect of IL-1b–neutralizing antibody on protein secretion,
compared with isotype control). Data represent mean 6
SEM values from n ¼ 3 primary ASM cell cultures.
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for NLRP3 (Figures 6A–6F) and caspase-1 protein (Figures
6G–6L), in accordance with the findings of Hirota and col-
leagues (19), these proteins are not detected in ASM bundles
in situ. Moreover, using protein homogenates from freshly iso-
lated ASM strips of human tracheas from three donors,
NLRP3 and caspase-1 were not detected by immunoblotting,
as shown in Figure 6M. In contrast, a clear band for NLRP3
and caspase-1 protein was evident in lysates from stimulated
THP-1 macrophages, run in parallel as a positive control, whereas
these proteins were expressed at lower concentrations in unsti-
mulated cells. Collectively, our results demonstrate that NLRP3
and caspase-1 are not expressed in ASM from human tracheal
tissue.
DISCUSSION
Our data demonstrate that the Pam3CSK4-mediated augmenta-
tion of TNF-a–induced IL-6 and IL-8 mRNA and protein con-
centrations is not mediated by IL-1b secretion via NLRP3
inflammasome activation in ASM cells. NLRP3 and caspase-1
are not detected immunohistochemically in situ, they are not
present in dissected ASM strips from human tracheas, and these
proteins are not expressed in ASM cells in vitro. Thus, the
NLRP3 inflammasome is not activated in ASM upon TLR2
ligation.
Recent in vivo and in vitro studies have implicated the
NLRP3 inflammasome as a potential therapeutic target in
asthma (1–4), although debate continues (22, 23). To date,
Figure 5. Pam3CSK4 does not affect TNF-a–induced
nucleotide-binding domain and leucine-rich repeat
protein–3 (NLRP3) mRNA and protein expression in ASM
cells. (A and B) Growth-arrested ASM cells were pretreated
with vehicle or Pam3CSK4 (1 mg/ml) for 1 hour, followed
by treatment with vehicle or TNF-a (10 ng/ml) for 0, 1, 2,
4, 8, and 24 hours. (A) NLRP3 and (B) caspase-1 mRNA
expression was quantified by real-time RT-PCR, and
results are expressed as fold increase compared with
vehicle-treated cells at 0 hour, expressed as mean 6
SEM values from (A) n ¼ 6 or (B) n ¼ 4 primary ASM cell
cultures. Statistical analysis was performed using two-
way ANOVA and then the Bonferroni post hoc test (where
an asterisk denotes a significant effect of treatment on
caspase-1 mRNA expression, compared with vehicle-treated
cells; P , 0.05). (C and D) Growth-arrested ASM cells were
pretreated with vehicle or Pam3CSK4 (1 mg/ml) for 1 hour,
followed by treatment with vehicle or TNF-a (10 ng/ml) for
24 hours. Whole cell lysates were prepared and immuno-
blotted for (C) NLRP3 and (D) caspase-1 protein, using
a-tubulin as the loading control. (C and D) Representative
blots of n ¼ 3 primary ASM cell cultures and lysates from
THP-1 monocytes, treated with or without phorbol myris-
tate acetate (PMA; 50 ng/ml), served as positive controls.
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several reports demonstrated the presence of the functional
NLRP3 inflammasome in asthmatic airway epithelia (19, 24,
25). The NLRP3 inflammasome–mediated production of IL-1b
in airway epithelial cells leads to airway neutrophilic inflam-
mation (19), which is the predominant phenotype of airway
inflammation in acute exacerbations (26, 27). Allen and col-
leagues in 2009 (24) demonstrated that the NLRP3 inflamma-
some expressed in airway epithelial cells and macrophages
is required for inflammation after influenza infection. Thus,
a growing body of research suggests that the NLRP3 inflam-
masome may be activated in the airways to promote increased
cytokine expression and a proinflammatory milieu during
infections.
Increasing evidence demonstrates that ASM cells play a role
in the amplification of inflammatory responses during infectious
exacerbations in asthma via augmented cytokine production
(18, 28–31). Our study is the first to examine the involvement
of the NLRP3 inflammasome and possible IL-1b secretion
in Pam3CSK4 and TNF-a–induced cytokine up-regulation in
ASM cells. Although Pam3CSK4 is primarily known as a
TLR2 agonist, its ability to activate the NLRP3 inflammasome
to release IL-1b has been demonstrated in macrophages (32).
This led us to examine the effects of IL-1b neutralization on
Pam3CSK4 and TNF-a–induced cytokine up-regulation. We
first demonstrated that IL-1b induces a significant increase in
IL-6 and IL-8 protein secretion by ASM cells in a concentra-
tion-dependent manner. We also demonstrated that the IL-1b–
induced up-regulation of IL-6 and IL-8 secretion is completely
inhibited by IL-1b–neutralizing antibody. These results show
that the IL-1b–neutralizing antibody can successfully neutralize
the effects of IL-1b on cytokine up-regulation in ASM cells.
However, the Pam3CSK4-induced up-regulation of IL-6 and
IL-8 protein secretion was not inhibited by the neutralization
of IL-1b. This finding suggests that IL-1b secretion is not involved
in TLR2 ligand–induced cytokine up-regulation in ASM cells.
In support of this, we also demonstrated that ASM cells trea-
ted with Pam3CSK4 and TNF-a do not secrete detectable con-
centations of IL-1b protein over 24 hours, although gene
expression is significantly augmented. For the NLRP3 inflam-
masome in ASM cells to be active in a classic manner, the
production and secretion of mature IL-1b should be observed
in response to Pam3CSK4 (33), because IL-1b secretion is
widely accepted as a surrogate marker for NLRP3 inflamma-
some activation. However, TLR2 ligation by Pam3CSK4
appears unable to induce assembly of the NLRP3 inflamma-
some and the processing of IL-1b secretion. We were unable
to detect the expression of NLRP3 and caspase-1 protein. To-
gether, our results provide evidence that the NLRP3 inflamma-
some is not activated to promote IL-1b maturation and
secretion in response to Pam3CSK4 and TNF-a in ASM cells.
This rules out the possibility that IL-1b secreted as a result of
Pam3CSK4-enhanced, TNF-a–induced IL-1b mRNA expres-
sion observed at an early time point (4 h) acts in an autocrine
manner to boost the further augmentation of IL-6, IL-8, and IL-
1b gene expression at later time points (24 h) via a positive
feedback loop.
The results presented here indicate important cell-type spec-
ificity in airway inflammation, because we demonstrate that the
robust up-regulation of proinflammatory cytokines by invading
pathogens may not be mediated by activation of the NLRP3
inflammasome and IL-1b secretion in ASM. Using primary cul-
tures of human ASM cells, we demonstrated that Pam3CSK4
robustly up-regulates TNF-a–induced IL-1b mRNA expression,
but does not significantly change the expression of NLRP3 and
caspase-1. Importantly, IL-1b is not secreted from ASM cells.
Thus IL-1b is unable to act in an autocrine manner to induce an
inflammatory milieu that mimics exacerbation in ASM cells by
promoting IL-6 secretion and up-regulation of the neutrophil
chemoattractant chemokine, IL-8. Moreover, although NLRP3
and caspase-1 are present in human airway epithelium (corrob-
orating Hirota and colleagues) (19), these proteins are not
detected in the nearby ASM bundles in immunohistochemical
analyses of human tracheas in situ.
Respiratory infections are key factors underlying asthma
exacerbations. By propagating and amplifying inflammation in
response to bacterial and viral pathogens, airway structural cells
play an important immunomodulatory role in asthma. We ex-
plored the role of the NLRP3 inflammasome and the secretion
of IL-1b from ASM cells in response to Pam3CSK4 activation,
and although TLR2 ligation robustly enhanced cytokine expres-
sion, this up-regulation was IL-1b–independent. Exacerbated
asthmatic symptoms are not effectively attenuated by current
pharmacological management. By addressing molecular mech-
anisms of exacerbation, our experiments have revealed a poten-
tially important cell type difference, that is, whereas the NLRP3
inflammasome is activated in human airway epithelium (19), the
TLR2-mediated enhancement of proinflammatory cytokine se-
cretion in the underlying ASM layer is NLRP3 inflammasome–
independent. Although the functional relevance of the restricted
localization of the NLRP3 inflammasome in the airways is un-
clear at present, crosstalk between airway structural cells (and
Figure 6. NLRP3 and caspase-1 are not expressed in human ASM from
tracheal tissue. (A–F) In situ immunohistochemistry of three human
tracheas donated for medical research (see Table 1 for subject charac-
teristics, i.e., Donors 1–3) for (A–F) NLRP3 and (G–L) caspase-1 protein
(brown ¼ positive stain) at 320 and 360 magnification. (M) Immuno-
blots of NLRP3 and caspase-1 in isolated airway smooth muscle strips
from three human tracheas (see Table 1 for subject characteristics, i.e.,
Donors 4–6). Lysates from THP-1 monocytes treated without or with
PMA (50 ng/ml) served as positive controls, and b-tubulin was used as
a loading control.
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inflammatory cells) remains a possibility. Thus, further studies are
warranted to develop new therapeutic strategies to combat asthma
exacerbations in the future.
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